Autism Disorder and Treatment Market - Overview
Autism spectrum disorder (ASD) is a group of complex neurological disorders characterized by varied patterns of behaviour, and problems with social communication and interaction. The major signs, and symptoms of ASD includes compulsive behaviour, inappropriate social interaction, learning disability, anxiety, sensitivity to sound, repetitive movements, and many others. As per the 2017 reviewed data suggested by Centers for disease control and prevention, it is observed that nearly 1 in 68 children has been diagnosed with autism spectrum disorder (ASD). It is also reported that the condition is 4.5 times more common among boys than among girls.
On considering the economic costs, it is observed that around USD 11.5 billion – 60.9 billion have been invested per year for patients dealing with ASD n the United States. In addition to medical costs, other behavioral interventions for children with ASD costs around USD 40,000 - 60,000 per child per year.
For instance, on June 1, 2017, the U.S. based Autism Society conducted 49th annual conference focuses on quality of life. Rising research & development activities have also attracted a great deal of attention. The Autism CARES Act extended federal coverage of autism research activities by five years with $1.3 billion funding. Despite these significant driving factors, there are some issues associated with market. Patent expiration of drugs is expected to decline the market growth in near future.
Ask For Sample Report: https://www.marketresearchfuture.com/sample_request/1605 .
Market Players Try to Find Their Winning Formulas to reach unmet needs
The Autism Disorder and Treatment market is currently dominated by various few players. Bristol-Myers Squibb and Otsuka Holdings Co., Ltd. are one of those by holding a strong share in the market. Bristol-Myers Squibb is a U.S. based pharmaceutical company and Otsuka Holdings Co., Ltd. has head office in Japan. Both the companies in collaboration introduced ABILIFY® (aripiprazole) drug for the treatment of conditions associated with autistic disorder. The drug had received approval November 20, 2009. Currently, there are only two FDA approved drugs for autistic disorder in the market i.e., Abilify (aripiprazole) and risperidone. Risperidone is a second-generation antipsychotic drug, received approval from FDA to treat autistic disorders in 2006.
Regional Analysis: Autism Disorder and Treatment Market
The Autism Disorder and Treatment Market is expected to be concentrated across the eight major countries such as US, Canada, France, UK, Germany, Spain, Italy, and, Japan. Regional market analysis reflects the dominance of developed world on the Autism disorder treatment market. North America leads the world and is closely followed by Europe. The Asian continent is led by Japan. A close observation will reflect the fact that increasing screening is the likely cause of increasing Autism cases. This reflects an untapped and unmet needs of the developing world. Thus the market will be dominated by developed regions in the years to come and only after advent of a specific drug will the developing region market pick up. Market for non-pharmacological treatment especially in the developing world will be more affected by government policies and rising incomes.
Due to the rising demand, and to meet the untapped and unmet needs various companies are coming up with innovative autism treatment products. For instance, RG7314, by F. Hoffmann-La Roche Ltd, is a potent small molecule antagonist of the V1A vasopressin receptor is under clinical trials to treat Autism spectrum disorders.
Access Complete Report Here: https://www.marketresearchfuture.com/reports/autism-disorder-treatment-market-1605 .
Research and Development (R&D) Companies
Medical Research Laboratories
Academic Medical Institutes and Universities
Key Players for Autism disorder and Treatment Market
Some of the key players in this market are:
GlaxoSmithKline plc (UK),
pfizer inc. (US),
Eli Lilly and Company (US).
Merck & CO Inc. (US),
Consern Pharma Private Limited (india)
Rest of Western Europe
Rest of Asia
Various other companies such as,
APeT Holding BV,
Coronis Partners Ltd.,
Heptares Therapeutics Limited,
Intra-Cellular Therapies Inc.,
Saniona AB, and others are continuously putting efforts to introduce new effective drugs to treat autism , and related problems.
Global key Players :
GlaxoSmithKline plc (U.K),
pfizer inc. (U.S.),
Eli Lilly and Company (U.S.).
Allergan (Ireland), Merck & CO Inc. (U.S.),
Teva Pharmaceutical Industries Ltd. (Israel),
Consern Pharma Private Limited (India) are some of the prominent players profiled in MRFR Analysis and are at the forefront of competition in the Global Autism Disorder and Treatment Market.
Topics Enclosed in Report:
Chapter: 1 Report Prologue
Chapter: 2 Market Introduction
Chapter: 3 Research Methodology
Chapter: 4 Market Dynamics
Chapter: 5 Market Factor Analysis
Chapter: 6 Global Autism Disorder And Treatment Market, By Types
Chapter: 7 Global Autism Disorder And Treatment Market, By Drugs
Chapter: 8 Global Autism Disorder And Treatment Market, By Regions
Chapter: 9 Competitive Landscape
Chapter: 10 Company Profile
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
For Inquiry: https://www.marketresearchfuture.com/enquiry/1605 .
Market Research Future Office No. 528,
Amanora Chambers Magarpatta Road,
Hadapsar, Pune – 411028
Phone: +1 646 845 9312
Email: [email protected]